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Background: Cissampelos sympodialis Eichl. (Menispermaceae) is a plant found in Northeastern and Southeast
of Brazil and hot water infusion of C. sympodialis root bark is largely used in the indigenous and folk medicine
to treat several inﬂammatory disorders, including asthma. Asthma is a chronic inﬂammatory allergic disease
characterized by airway hyperreactivity (AHR), eosinophil tissue inﬁltration and lung remodeling. The aim of
this study was to evaluate the therapeutic effect of C. sympodialis and its isolated alkaloid warifteine on aller-
gen triggered airway hyperreactivity (AHR) and lung remodeling in murine model of asthma.
Methodology/principal ﬁndings: The oral pre-treatment with C. sympodialis or warifteine inhibited allergen-
induced AHR to inhaled methacholine and IL-13 levels in the bronchoalveolar lavage (BAL). In order to inves-
tigate the therapeutic potential of C. sympodialis and warifteine, animals were treated 1 h after the last oval-
bumin (OVA) challenge in sensitized animals. Similarly to the pre-treatment, post-treatment with warifteine
was effective to inhibit signiﬁcantly AHR to inhaled methacholine and to reduce IL-13 levels in the BAL. In
addition, oral pre- or post-treatments with C. sympodialis or warifteine reduced OVA-induced eosinophil tis-
sue inﬁltration, mucus production and subepithelial ﬁbrosis to values similar to nonallergic controls.
Conclusions: Our data show the anti-allergic and immunoregulatory properties of C. sympodialis, acting most-
ly through the active compound warifteine, to inhibit the airway hyperreactivity and lung remodeling
through a mechanism at least partially dependent of IL-13 and eosinophil inhibition. Therefore placing war-
ifteine as an interesting therapeutic candidate in allergic inﬂammation and corroborating the folk medicine
use of C. sympodialis as anti-allergic plant.© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Asthma is a chronic inﬂammatory disease characterized by eosin-
ophil tissue inﬁltration, airway hyperreactivity (AHR) and lung remo-
deling [1]. Anti-inﬂammatory treatment with inhaled glucocorticoid
alone or combined therapy of corticosteroids with long-acting β2-
agonist bronchodilators is the current preconized therapy for asthma.
Although, most asthmatics respond to these treatments, 5–10% of
patients are entirely insensitive to corticosteroids. In addition, some
patients require additional oral glucocorticoids, and long-term use
of corticosteroids has been strongly associated with a number ofzam).
evier OA license.adverse effects [2,3]. Thus, there is a need for new anti-asthmatic
drug development.
Medicinal plants and their bioactive molecules are alternative
options to conventional therapies for many diseases. Cissampelos
sympodialis Eichl. (Menispermaceae) is a plant species found in
Northeastern and Southeast of Brazil. A hot water infusion of C. sym-
podialis root bark is largely used in the indigenous and folk medicine
to treat several inﬂammatory disorders, including asthma [4]. Phyto-
chemical analysis of C. sympodialis root extracts leads to isolation of
several alkaloids, of which warifteine has shown pharmacological
effects [5–7]. In order to investigate the effect of C. sympodialis in
immunological responses, previous studies showed that this plant
enhanced IL-10 and IFN-γ levels in spleen cells from allergic mice
and IL-10 levels in macrophage cultures [8,9]. This modulatory effect
of C. sympodialis was correlated with decreased Ig-E production.
Fig. 1. Structure of warifteine.
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recent published data showed that C. sympodialis and warifteine
strongly reduced the eosinophilic inﬂammation into the bronchoal-
veolar lavage and pleural cavities in ovalbumin (OVA) sensitized
mice [10]. This effect was dependent of cysteinyl leukotrienes gener-
ation and lipid body formation observed in activated eosinophils. C.
sympodialis and warifteine were also capable of inhibiting the gener-
ation of the eosinophil chemoattractant factor, eotaxin. In addition,
recent study showed in an experimental model of respiratory allergy
to Blomia tropicaliswhich is the most important indoor allergen asso-
ciated with asthma and rhinitis that the hydroalcoolic extract of C.
sympodialis leaves andwarifteine signiﬁcantly reduced eosinophil mi-
gration and modulated Th2 cytokine production inducing IL-5 levels
reduction in the bronchoalveolar lavage, while presenting high levels
of the anti-inﬂammatory cytokine IL-10 [11].
Among the effects observed on inﬂammatory leukocytes, mast
cell activation was also modiﬁed by warifteine. In vitro studies
showed that warifteine inhibited mast cell degranulation induced
by immunological or pharmacological challenge [12]. In these previ-
ous studies, it was also observed that warifteine decreased the imme-
diate allergic reactions such as anaphylactic shock by IgE dependent
mechanisms and thermal hyperalgesia.
The effects of C. sympodialis and warifteine on airway hyperreac-
tivity and lung tissue pathological changes in OVA-induced allergic
airway disease have not been addressed. The aim of this study was
to evaluate the effectiveness of C. sympodialis on airway hyperactivity
and collagen ﬁbers and mucus production. For this purpose we used
either the standardized hydroalcoholic extract of the C. sympodialis
leaves, as well as, the C. sympodialis-derived alkaloid warifteine in
OVA-induced lung inﬂammation in actively sensitized mice.2. Materials and methods
2.1. Preparation of C. sympodialis extract and warifteine puriﬁcation
Leaves from C. sympodialis were obtained from the Botanical Gar-
den of the Laboratório de Tecnologia Farmacêutica/Universidade Fed-
eral da Paraíba (voucher specimen Agra 1456). The leaves were dried
at 50 °C in an oven and pulverized. The powder was extracted with
70% ethanol in water at 70 °C for 5 days. The dried extract was dis-
solved in water; ﬁltered and known volumes were dried to determine
the ﬁnal concentration of the water-soluble components. All doses
are expressed in terms of the concentration of the soluble compo-
nents (mg/kg of body weight). The yield was 22% on average, based
on solid residues present [13]. C. sympodialis extract was dissolved
in sterile water immediately before use. The extract used in all exper-
iments described in this paper had a nominal concentration of 0.95%
of warifteine [11].
The extract of C. sympodialis was submitted to procedures aimed
to isolate the alkaloids, using column and thin layer chromatography
(TLC). Brieﬂy, the extract was dissolved in 3% HCl and extracted sev-
eral times with CHCl3. The aqueous fraction was basiﬁed with NH4OH
to pH 9 and again extracted with CHCl3. The CHCl3 extract was
washed with H2O, dried (MgSO4) and the solvent evaporated to af-
ford the total tertiary alkaloid fraction (TTA). The TTA was subjected
to column over alumina, eluting with hexane containing increasing
amounts of CHCl3, CHCl3 with increasing amounts of MeOH and ﬁnal-
ly with MeOH. The fraction eluted with CHCl3–MeOH (49:1), after
further puriﬁcation by TLC (1.0 mm layer), yielded the isolation of
the bisbenzylisoquinoline alkaloid warifteine (0.031%). The identiﬁ-
cation of the warifteine was performed by analyzing 1H and 13C
NMR spectral data compared with those published in the literature
(Fig. 1) [11]. Warifteine was quantiﬁed in the leaf extract (CsE) by
means of High Performance Liquid Chromatography (HPLC) with
ultraviolet detection and it was calculated at 96.4% pure.2.2. Animals
Female BALB/c mice weighing 16–20 g were used. They were
obtained from Oswaldo Cruz Foundation breeding unit. Animals
were maintained with food and water ad libitum in a room with tem-
perature ranging from 22 to 24 °C and a 12 h light/dark cycle. This
study was carried out in accordance with the recommendations of
the Brazilian National Council of Control of Animal Experimentation
(CONCEA). The protocols were approved by the Animal Welfare Com-
mittee of the Oswaldo Cruz Foundation (CEUA/FIOCRUZ protocol # L-
002/08).
2.3. Asthma model in actively sensitized mice
OVA-induced allergic airway disease was generated in mice as de-
scribed previously [14]. Brieﬂy, mice (n=8) were sensitized with in-
traperitoneal injection of OVA (10 μg/mouse) and Al(OH)3 (10 mg/
mL) in 0.9% NaCl solution (saline; 0.2 mL) on days 1 and 10. From
day 19 to day 24 after sensitization, mice were challenged daily for
20 min with OVA (5%) in phosphate buffered saline (PBS) by aerosol.
Aerosolized PBS was administered to sensitized mice as a negative
control. These procedures were performed in a 30×20×10 cm acrylic
chamber and the aerosol was generated with an ultrasonic nebulizer.
2.4. Treatments
To evaluate the effect of C. sympodialis and warifteine in airway
hyperreactivity and lung histopathological changes, mice were trea-
ted 1 h before (pre-treatment) or 1 h after (post-treatment) the last
aerosol OVA challenge. C. sympodialis extract (40 mg/kg), warifteine
(2 mg/kg) or dexamethasone (2 mg/kg) was administered via oral
route (p.o). Of note, the C. sympodialis extract and warifteine doses
were used according to previous reports [9–11].
2.5. Airway hyperreactivity analysis
Airway hyperreactivity (AHR) was analyzed in mice using non-
invasive whole-body plethysmography (Buxco, Sharon, CT) one day
after the last OVA challenge. AHR was measured following aerosoliza-
tion of PBS followed by increasing concentrations of methacholine (0,
6, 25 mg/mL; Sigma-Aldrich) for 2 min into the chamber. AHR was
expressed as an average enhanced pause (Penh). There was an inter-
val of 10 min between each aerosol exposure and within this period
of time the Penh values had returned to baseline.
2.6. Bronchoalveolar lavage (BAL) and quantiﬁcation of IL-13
Animals were euthanized by CO2 and the trachea was surgically
exposed and cannulated at 6 or 24 h after the last allergen challenge.
BAL was collected from the mice by washing the lungs with 1 mL PBS.
Samples of BAL were centrifuged at 500 g for 8 min at 4 °C to obtain
the supernatants. Then levels of IL-13 were measured according to
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Systems).2.7. Lung histology
Lungs were inﬂated by injecting 1.0 mL of 4% buffered formalin
through the catheter used to perform BAL. Lungs were then removed,
ﬁxed in the same solution, and embedded in parafﬁn. Lung sections of
5-μm thickness were stained with Sirius red, Mason's trichrome, and
periodic acid-Schiff (PAS) according to standard protocols and exam-
ined under light microscopy. Analysis of tissue sections and captured
images was performed by using a computer-assisted image analyzer
(Image-Pro Plus Version 4.1 for Windows, Media Cybernetics, LP, Sil-
ver Spring, MD, USA). One observer who was unaware of the experi-
mental setting examined all tissue sections randomly. Digital
photographs of at least 10 bronchovascular bundles per tissue section
(with bronchioles cross-sectional diameters ranging from 120 to
250 μm) were obtained under light microscopy at ×400 magniﬁca-
tions. For quantifying eosinophil inﬁltration of the pulmonary tissue,
the total number of eosinophils was counted in the ten areas, and
the mean was expressed as eosinophils/high power ﬁeld (HPF).
Mucus secretion from goblet cells of the bronchial epithelium was
quantiﬁed by the staining of sections with PAS. Goblet cells were rec-
ognized by the intense dark red staining of their mucus content with
PAS, and their characteristic distended lateral border and basal nucle-
us. The number of goblet cells was expressed as the percentage of
positive cells in at least 500 cells of the bronchial epithelium. The
Mason's trichrome dye was used to stain collagen ﬁbers in tissue.
Density of collagen ﬁbers was deﬁned by the positively stained area
in relation to total tissue in the area of the bronchovascular bundles
per millimeter squared, at a magniﬁcation of ×100.Fig. 2. Effect of C. sympodialis treatment on airway hyperreactivity (AHR) development
and IL-13 production. OVA-sensitized mice were treated with a single oral dose of
dexamethasone (2 mg/kg) 1 h before, or C. sympodialis extract (40 mg/kg) 1 h before
(pre-) or 1 h after (post-) the last OVA challenge. PBS aerosolized mice were used as
control. (A) AHR was measured by aerosolization of PBS followed by increasing con-
centrations of methacholine. AHR was analyzed 24 h after the last allergic challenge
and expressed as an average enhanced pause (Penh). (B) IL-13 production was mea-
sured in BAL 24 h after the last allergic challenge. Results are expressed as the mean
±SEM from at least six animals. *, signiﬁcantly different from PBS-challenged group
(P≤0.05). +, signiﬁcantly different from allergen-challenged group (P≤0.05).2.8. Statistical analysis
Statistical analysis was carried out using the statistical software SPSS
for Windows (Version 10.0.1, SPSS Inc., 1989–1999, USA) or GraphPad
Prism statistical analysis and graphing software (GraphPad, San Diego,
CA). Data were analyzed by ANOVA followed by Newman Keuls t test
or Dunnett's test. Correlations between the densities of positive cells
and the collagen ﬁbers were assessed using the Spearman rank correla-
tion coefﬁcient. Values are expressed as means±SEM. The level of sig-
niﬁcance was set at Pb0.05.3. Results
3.1. C. sympodialis and its alkaloid warifteine inhibit AHR and IL-13
production
OVA sensitization and airway challenge led to the development of
AHR in mice illustrated by signiﬁcant increases in Penh values com-
pared with PBS-challenged control mice. As shown in Fig. 2A, the
pre-treatment with C. sympodialis reduced AHR to inhaled methacho-
line (25 mg/mL) observed 24 h after allergen challenge. This effect
was similar to the glucocorticoid dexamethasone a potent anti-
inﬂammatory drug. The pre-treatment with C. sympodialis derived-
alkaloid warifteine was also effective in blocking AHR (Fig. 3A).
The involvement of IL-13 in AHR development is well described.
OVA-induced allergic airway inﬂammation leads to elevated levels
of IL-13 when compared to PBS challenged animals (Figs. 2B and
3B). As illustrated in the same ﬁgures, OVA-sensitized and challenged
mice pre-treated with either C. sympodialis or warifteine showed a
signiﬁcant reduction in IL-13 levels, comparable to dexamethasone
treated animals.Fig. 3. Effect of warifteine treatment on airway hyperreactivity (AHR) and IL-13 pro-
duction. OVA-sensitized mice were treated with a single oral dose of dexamethasone
(2 mg/kg) 1 h before, or warifteine (2 mg/kg) 1 h before (pre-) or 1 h after (post-)
the last OVA challenge. (A) AHR was measured by aerosolization of PBS followed by in-
creasing concentrations of methacholine. AHR was analyzed 24 h after the last allergic
challenge and expressed as an average enhanced pause (Penh). (B) IL-13 production
was measured in BAL 6 h after the last allergic challenge. Results are expressed as the
mean±SEM from at least six animals. *, signiﬁcantly different from PBS-challenged
group (P≤0.05). +, signiﬁcantly different from allergen-challenged group (P≤0.05).
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podialis and its active derivative warifteine, animals were treated
1 h after the last OVA challenge in sensitized animals. Similarly to
the pre-treatment, oral post-treatment with warifteine but not
with C. sympodialis extract (data not shown) was able to inhibit
AHR in a signiﬁcant manner. In addition, post-treatment with warif-
teine reduced IL-13 BAL levels detected 6 h after the last OVA
challenge in the asthma model (Fig. 3B). These data indicate that
C. sympodialis, mostly through the active compound warifteine, is
capable to ameliorate an established inﬂammatory allergic reaction.Fig. 4. Effects of C. sympodialis and warifteine treatments in airway mucus deposition. Twen
embedded in parafﬁn, and sectioned. The tissue section slides were stained with periodic ac
OVA-sensitized mice were treated with a single oral dose of dexamethasone or warifteine (
(post-) the last OVA challenge. PBS aerosolized mice were used as control. (A) Microscopic
with PAS. Data are representative of two independent experiments (n=6). *, signiﬁca
allergen-challenged group (P≤0.05).3.2. Effects of C. sympodialis and warifteine in mucus accumulation
The evaluation of airway mucins assessed by PAS staining is shown
in Fig. 4A. The analysis of airway mucins demonstrated a signiﬁcant
metaplasia of goblet cells and mucus accumulation 24 h after the last
OVA challenge in actively sensitized mice. Oral pre- or post-treatment
with C. sympodialis or pre-treatment with warifteine reduced OVA-
induced mucus accumulation and the percentage of mucus producing
cells to values similar to nonallergic controls (Fig. 4B). Pre-treatment
with dexamethasone showeddecreasedmucus production as expected.ty-four hours after the last day of challenge, lungs were inﬂation-ﬁxed in 4% formalin,
id-Schiff (PAS) for evaluation of airway mucins and number of mucus-producing cells.
2 mg/kg) 1 h before, or C. sympodialis extract (40 mg/kg) 1 h before (pre-) or 1 h after
analysis of stained tissue sections. (B) Quantitative analysis of tissue sections stained
ntly different from PBS-challenged group (P≤0.05). +, signiﬁcantly different from
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eosinophil inﬁltration in OVA-induced airway inﬂammation
Eosinophil activation and recruitment are hallmarks of allergic
disease and tissue eosinophil inﬁltration has been associated with
collagen deposition and lung remodeling. The effect of C. sympodia-
lis or warifteine oral treatment on OVA-induced eosinophil tissue
inﬁltration was investigated. As shown in Fig. 5A, Sirius red stained
lung sections revealed an increased leukocyte inﬁltration comprised
mostly by a marked perivascular eosinophilia in OVA-challenged
allergic mice when compared to nonallergic mice. Oral pre-
treatment with C. sympodialis or warifteine signiﬁcantly inhibitedFig. 5. Effect of C. sympodialis and warifteine treatment in eosinophil tissue inﬁltration follow
lenge, lungs were inﬂation-ﬁxed in 4% formalin, embedded in parafﬁn, and sectioned. The t
sensitized mice were treated with a single oral dose of dexamethasone or warifteine (2 mg/k
the last OVA challenge. PBS aerosolized mice were used as control. (A) Microscopic analysis
red. *, signiﬁcantly different from PBS-challenged group (P≤0.05). +, signiﬁcantly differenOVA-induced eosinophil tissue inﬁltration similar to pre-treatment
with dexamethasone (Fig. 5B). Post-treatment with C. sympodialis
extract was also able to signiﬁcantly inhibit eosinophil tissue inﬁl-
tration observed after 24 h (Fig. 5A and B).
3.4. Inhibition of collagen ﬁber deposition by C. sympodialis
and warifteine
Airway remodeling is associated with clinical outcomes in asth-
matic patients and contributes to thickening of airway walls leading
to hyperreactivity and narrowing of airways. As shown in Fig. 6A,
OVA induced signiﬁcant subepithelial ﬁbrosis with collagen ﬁbering OVA-induced allergic airway disease. Twenty-four hours after the last day of chal-
issue section slides were stained with Sirius red for eosinophil tissue evaluation. OVA-
g) 1 h before, or C. sympodialis extract (40 mg/kg) 1 h before (pre-) or 1 h after (post-)
of stained tissue sections. (B) Quantitative analysis of tissue sections stained with Sirius
t from allergen-challenged group (P≤0.05).
Fig. 6. Effects of C. sympodialis and warifteine treatments in collagen ﬁber deposition. (A) Lung serial sections were embedded in parafﬁn by routine methods and stained with
Mason's trichrome stain to collagen ﬁber observations. OVA-sensitized mice were treated with a single oral dose of dexamethasone or warifteine (2 mg/kg) 1 h before or C. sym-
podialis extract (40 mg/kg) 1 h before (pre-) or 1 h after (post-) the last OVA challenge. PBS aerosolized mice were used as control. (A) Microscopic analysis of stained tissue sec-
tions. (B) Quantitative analysis of collagen ﬁber density was expressed in percentage. (C) Correlation between eosinophil tissue inﬁltration and collagen ﬁber deposition and (D)
correlation between eosinophil tissue inﬁltration and mucus-producing cells. *, signiﬁcantly different from PBS-challenged group (P≤0.05). +, signiﬁcantly different from allergen-
challenged group (P≤0.05).
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compared to nonallergic controls. As observed in Fig. 6A and quanti-
ﬁed in Fig. 6B, oral treatment with C. sympodialis (pre or post) or war-
ifteine (pre) reduced OVA-induced collagen deposition to values
similar to nonallergic controls (Fig. 6A, B). In accordance to a role
for tissue eosinophils in collagen and mucus deposition and lung
remodeling, there is a strong correlation between eosinophil inﬁltra-
tion and collagen deposition (correlation coefﬁcient of 0.651,
Pb0.003) and mucus (correlation coefﬁcient of 0.723, Pb0.001) in
the lungs (Fig. 6C, D).4. Discussion
In this study we evaluate the effect of Cissampelos sympodialis and
its isolated alkaloid warifteine in a murine asthma model. We provide
novel evidence related to the anti-allergic and immunoregulatory
properties of C. sympodialis, acting mostly through the active com-
pound warifteine, to inhibit the airway hyperreactivity and lung
remodeling via a mechanism at least partially dependent of IL-13
and eosinophil inhibition.In order to test the hypothesis that C. sympodialis has anti-allergic
properties and potential for anti-asthmatic use, the effect of ethanolic
extract of C. sympodialis leaves and its derived-alkaloid warifteine to
prevent or ameliorate AHR and lung remodeling were investigated.
Oral treatment with C. sympodialis 1 h before the last ovalbumin chal-
lenge signiﬁcantly reduced AHR. Development of AHR depends on
airway inﬂammation and smooth muscle lung contraction induced
by different stimuli including IL-13, IL-4 and cysteinyl leukotrienes
[15–17]. Accumulating evidence has placed IL-13 as a key mediator
of AHR due to the protective effect demonstrated by different strate-
gies of disruption of IL-13 production and/or effects [16]. To gain in-
sights on the mechanism of action of C. sympodialis its role in IL-13
production was analyzed. In parallel to the AHR inhibition, we ob-
served a reduced level of IL-13 in bronchoalveolar lavage of orally
treated with C. sympodialis and challenged mice. Thus suggesting
that, at least in part, the mechanism involved in C. sympodialis inhib-
itory effect on OVA-induced AHR may occur through inhibition of IL-
13 production. In order to investigate candidate compounds to anti-
asthmatic effect from C. sympodialis the isolation of one bisbenzyliso-
quinoline alkaloid warifteine was performed [6]. Similar to the one
observed with C. sympodialis, oral treatment with warifteine inhibited
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teine represents the main active component responsible for the ef-
fects of C. sympodialis. However, other constituents mainly alkaloids
such as methylwarifteine, milonine and roraimine may also contrib-
ute to the anti-allergic effects of C. sympodialis extract.
Of note, warifteine also has an additional property that may ex-
plain its inhibitory effects on AHR. Previous in vitro and in vivo studies
demonstrated direct spasmolytic effects and tracheal muscle contrac-
tion inhibition of warifteine [6,7,13,15]. In addition, warifteine treat-
ment was very effective impairing in vivo lipid body biogenesis and
BAL levels of LTC4 [10] which is produced within eosinophil lipid bod-
ies recruited to BAL in the asthma model [18].
As key components in asthma, lung eosinophils inﬂux during in-
ﬂammatory response has been demonstrated as important players
of progressive tissue damage and lung remodeling [19–21]. Eosino-
phils are multifunctional leukocytes capable of producing immuno-
regulatory cytokines and lipid mediators and are actively involved
in allergic disease through regulation of Th2-type immune responses
[22]. C. sympodialis and warifteine also signiﬁcantly reduced the eo-
sinophil inﬂux into the lung tissue of OVA-induced allergic inﬂamma-
tory disease in mice. Accordingly, we have showed that C. sympodialis
and its isolated alkaloid warifteine reduced eosinophil recruitment
and activation in broncoalveolar lavage as well as into pleural cavity
of OVA sensitized mice in part through mechanisms dependent of
eotaxin [10].
Allergic lung inﬂammation also induces changes in tissue pheno-
type named hyperplasia of goblet cells leading to excessive mucus
production causing airway obstruction [23] and collagen deposition
leading to remodeling of the airways. An array of molecules might
trigger mucus production but IL-13 has been mentioned as a pivotal
stimulus [24]. Mice orally treated with C. sympodialis and warifteine
showed a diminished mucus production in lung tissue. Airway remo-
deling is characterized by altered composition, content, and organiza-
tion of cellular and molecular constituents of the airway wall [1]. Oral
treatment with C. sympodialis also preserved structural components
of lung tissue such as airway smooth muscle (ASM) mass, distance
between epithelium and ASM cells, proliferation of blood vessels, air-
way edema, goblet cell numbers, collagen ﬁber deposition and mucus
production. Deposition of collagen ﬁbers and mucus has been de-
scribed as airway change able to cause narrowing of airway, rigidness,
loss of elastic recoil and reversible obstruction [1]. C. sympodialis and
warifteine reduced collagen ﬁber deposition and mucus in lung tis-
sue. These data correlated to decrease of eosinophil numbers in the
tissue. Previous studies related that different stimuli can initiate air-
way remodeling before the appearance of asthma symptoms suggest-
ing remodeling as contributive phenomena to lung inﬂammation and
AHR development, and there is compelling evidence that tissue eosin-
ophil accumulation contributes to lung remodeling in OVA-induced
airway allergic disease since animals genetically ablated in eosino-
phils were signiﬁcantly protected from peribronchiolar collagen de-
position and increases in airway smooth muscle [25].
In this work we demonstrated for the ﬁrst time that C. sympodialis
and its isolated alkaloid warifteine inhibits airway hyperreactivity
and lung remodeling known as the main asthma features and we pro-
vide evidence that the protective effect occurs partially by an IL-13
dependent mechanism. These ﬁndings, together with previous re-
ports of this plant and warifteine inhibiting anaphylactic shock reac-
tion in OVA sensitized mice, allergic pleurisy and pulmonary
inﬂammation; suggest their therapeutic potential as anti-allergic
and anti-asthmatic [9,26,10]. This alkaloid also reduced mast cell
degranulation and hyperalgesia response in rats [12]. Of interest for
potential therapeutic applications, both C. sympodialis extract and pu-
riﬁed warifteine showed unique post-treatment properties via oral
administration maintaining the anti-allergic inhibition of AHR, IL-13
production and lung eosinophil inﬁltration even when administered
after the installed allergic process.5. Conclusion
Indigenous and other people living in non-developed countries
use C. sympodialis as a preventive method to asthma condition. Our
data corroborate the folk anti-allergic medicine use of C. sympodialis.
In addition, our ﬁndings indicate that the anti-allergic and immuno-
regulatory properties of C. sympodialis occur mostly through the ac-
tive compound warifteine, to inhibit the airway hyperreactivity and
lung remodeling through a mechanism at least partially dependent
of IL-13 and eosinophil inhibition. Therefore, warifteine is suggested
as an interesting therapeutic candidate in allergic inﬂammation.Acknowledgments
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CS: Cissampelos sympodialis
DEX: Dexamethasone
WAR: Warifteine
OVA: Ovalbumin
AHR: Airway hyperreactivity
IL-13: Interleukin-13
Penh: Enhanced pause
BAL: Bronchoalveolar lavage
PAS: Periodic acid-Schiff
PBS: Phosphate buffered saline
Pre/Post: Pre-treatment/Post-treatment
